Storia in 3 fonti

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

Raccontata damorningstar.comhealio.commedpagetoday.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mesi fa

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and…

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

originale

medpagetoday.com1 mesi fa

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

Less frequent dosing could support better long-term adherence, says researcher

Leggi questa versione → originale

healio.com1 mesi fa

Berobenatide shows promise for monthly GLP-1 dosing

NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or overweight, with and without type 2…

Leggi questa versione → originale

Timeline cronologica

1. sabato 6 giugno 2026·morningstar.com
   

   First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

   First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

2. sabato 6 giugno 2026·healio.com
   

   Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes

   NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented…

3. sabato 6 giugno 2026·morningstar.com
   

   Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

   Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

4. sabato 6 giugno 2026·morningstar.com
   

   Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

   Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

5. sabato 6 giugno 2026·morningstar.com
   

   Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

   Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

6. domenica 7 giugno 2026·healio.com
   

   Berobenatide shows promise for monthly GLP-1 dosing

   NEW ORLEANS — New data from three phase 2b studies demonstrate substantial weight loss with berobenatide, an ultralong-acting GLP-1 receptor agonist, in people with obesity or…

7. domenica 7 giugno 2026·morningstar.com
   

   Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

   Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

8. lunedì 8 giugno 2026·medpagetoday.com
   

   Monthly GLP-1 for Obesity Promising as More Manageable Alternative

   Less frequent dosing could support better long-term adherence, says researcher

9. lunedì 8 giugno 2026·morningstar.com
   

   Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results

   Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results